



INVESTOR PRESENTATION

Disrupting the varicose vein market with Sonovein®

July 2025




Executive summary

- **A disruptive approach to varicose vein treatment:** SONOVEIN® is totally **non invasive** and **robotic** driven
- **Huge market:** varicose veins affect 1 in 3 adults, 13 B\$ total market
- **Proven technology:** 90% to 100% efficacy*, zero serious adverse event, 3 000+ veins treated, commercial PoC
- **US market path:** FDA-approved pivotal study results expected Summer 2025, FDA approval expected 2026
- **Commercial strategy:** accelerate on EU + Middle East markets, during US + China reg. approval processes
- **China path:** strong local partnership and joint-venture ramp-up for domestic and imported devices
- **R&D:** Minimum Viable Product reached in 2024, transformative improvements planned for 2025 and 2026
- **Financials:** from 2025 onward, expected strong revenues growth from commercial acceleration.

Market Overview



Varicose Veins: a widespread condition



What are Varicose Veins?

Varicose veins are swollen, twisted subcutaneous veins of the lower leg

Defective of the valves results in reflux of blood in the veins


Incompetent saphenous veins often have to be eliminated

The venous system


Superficial compartment
Cosmetic impact

Saphenous compartment
Often incompetent

Deep system
Main venous stream



ONE in THREE adults



31% of adults aged 18 to 64 are affected by varicose veins

Source: Maurins et al., 2008



From invasive to intelligent: Vein care reimaged

Stripping

Invasive ++



Surgery

- ⊗ Surgical vein removal
- ⊗ Requires anaesthesia
- ⊗ Long recovery
- ⊗ Higher risk of complications

Endovenous

Minimally invasive, last market shift



Laser, Radiofrequency
Glue

- ⊗ Laser, RF, or glue via catheter
- ⊗ Still requires sterile field
- ⊗ Risk of recurrence and side effects
- ⊗ Manual technique = variable results

Sonovein®

Non-invasive, next market shift



- ✓ Fully robotic with real-time ultrasound imaging
- ✓ 0 serious adverse events to date
- ✓ Walk-in, walk-out in under 1 hour
- ✓ One-operator, outpatient procedure
- ✓ Built-in data capture & future AI integration



Varicose Veins: a multibillion \$ market potential aligned with current market trends



\$13B

Current medical costs for Varicose Vein treatments worldwide



5M+

Annual addressable procedures



50% of people are afraid of surgery as varicose veins are not life-threatening, some patients refuse surgical treatments



Seamless integration into **aesthetic and cosmetic centers** outside the surgical field.

6,5% annual growth in Varicose Veins patients driven by

- 1 Age
- 2 Obesity
- 3 Lifestyle

54% of undiagnosed patients in industrialized countries


Largely **unmet medical need** in emerging countries + China

SONOVEIN is often the **only suitable option** for patients refusing surgery

SONOVEIN potentially addresses a major out-of-pocket **aesthetics market**



Sonovein value creation for medical devices in a multibillion \$ market potential



sonovein[®]


A game-changing technology



HOW SONOVEIN® WORKS



A game changing Technology: Robotic, Non-invasive




The energy is delivered via the **extra-corporeal treatment probe**.

The high-energy ultrasound waves propagate **through the skin** and are focused on a portion of **the target tissue**, generating **controlled heating** and causing the ablation of tissue within the focal area.

The process is then repeated in a **stepwise fashion** with **robotic driven** movements.

The tissue and its reaction is **monitored in real-time** with embedded ultrasound imaging.

High Intensity Focused Ultrasound (HIFU) Waves



Non-invasive



No scars



No infection




No recovery room



HOW SONOVEIN® WORKS



A game changing Technology: Robotic, Non-invasive




Robotic treatment head with embedded ultra-sound imaging

Robotized head

Consumable:
Cooling and coupling
Technology (through
Epack™)

Ultrasound imaging probe

HIFU transducer



Millimetric treatment accuracy



[Video link](#)

INTELLECTUAL PROPERTY

Active patents :
134 granted, 170 filed, 23 families

in HIFU procedure safety &
efficacy, system design and
application

**Strong barriers against future
competitive threats**

- | | |
|------------------|--------------------------|
| 1 Robotized head | 4 Rear handle and brakes |
| 2 Touchscreen | 5 Ultrasound probe |
| 3 Treatment head | 6 Cooling system |



ONE DEVICE. MANY CLINICAL SCENARIOS.



From tortuous veins to retreatments—Sonovein[®] adapts where others can't.

One system.

Full flexibility.

Sonovein allows you to expand your treatment offering—without increasing complexity.



Treat cases that are often untreatable with traditional methods:

- Short segments & CHIVA-style cases – without surgery
- Tortuous veins – difficult or impossible to catheterize
- Perforators – especially in ulcer patients
- Allergy-prone patients – avoid glue, foam, or chemicals
- Blood disorders – where puncturing is contraindicated
- Post-treatment recurrences – even after glue, RF, laser or stripping

sonovein[®]

A product ready for scale-up



A PRODUCT READY FOR SCALE-UP

Now a mature device: Effective and safe



Over 3,000 Vein treatments to date

- 90% to 100% efficacy*
- 0 severe adverse event**
- Treatment duration $\leq 1h$



Established international presence

- Commercial sites in 10+ countries
- Presence in EU, Middle East, Asia, US
- Top centers at more than 100 treatments/year



CE Mark in Europe

Latest generation of Sonovein in the process to obtain the new MDR CE marking



FDA feasibility study: finalized 2022

FDA pivotal study: results expected Q3 2025

FDA approval: submission planned for Fall 2025





A PRODUCT READY FOR SCALE-UP



Now a mature device: Effective and safe


Selected publications and congress presentations show **90% to 100%** efficacy, on **6+ sites** across Europe, across **hundreds of patients**, up to **3-year follow-up**, in **commercial** routine

TYPE OF RESULT	AUTHOR	EFFICACY RESULTS	TITLE	Reference
Publication Public	Prof. Izquierdo Lamoca Madrid, Spain	2-Year Results on 204 veins : Occlusion rate : 94,3% at 12 Months / 95,5% at 24 Months	High Intensity Focused Ultrasound Treatment for the Chronic Venous Disease based on the CHIVA Strategy	Journal of Vascular Surgery , 2025
Publication Public	Prof. Casoni Parma, Italy	Out of 262 legs analyzed, main pain score was 1,03 ± 1,27 . HIFU is an almost pain-free procedure	Comparing anesthesia protocols in High Intensity Focused Ultrasound treatments: The HIFU-pain study	Phlebology , 2024
Publication Public	Prof. Casoni Parma, Italy	Out of 188 limbs treated, shrinkage/closure rate: 97,6% at 6 Months / 98,3% at 12 Months	HIFU in treating GSV vein incompetence: Perioperative and 1-year outcomes	Phlebology , 2024
Congress Presentation Public	Prof. Casoni Parma, Italy	2-Year Results : 362 veins treated 16 Perforators = 94% Occlusion Rate	What's new ? – High Intensity Focused Ultrasound (SONOVEIN)	Italian Society of Physiology Roma, Italy, 2024
Publication Public	Dr. Elias Englewood, USA	First Ever SONOVEIN Chapter written in an American Reference Book	Chapter 45: High Intensity Focused Ultrasound (HIFU) for chronic venous disease	Handbook of Venous and Lymphatic Disorders , Edited by Glociczki, USA, 2024
Congress Presentation Public	Dr. Rodriguez Carvajal Marbella, Spain	90% on 205 Veins	High Intensity Focused Ultrasound (HIFU)	Vein In Venice , Venice, Italy, 2024
Congress Presentation Public	Dr. Stalnikiewicz Lille, France	100% on GSV / 70 – 80% on Perforators	High Intensity Focused Ultrasound (HIFU): short mid-term results	
Publication Public	Dr. Reyero & Izquierdo Madrid, Spain	3-Year Results on 119 Patients: 94,1% (119 patients)	Treatment with Localized High Intensity Ultrasound ... 3-Year Results	Angiologia , 2023
Congress Presentation Public	Dr. Steinbacher Melk, Austria	100% (23 veins)	First Experience with Sonovein HD	AVF 2023 , San Antonio, Texas, 2023
Congress Presentation Public	Prof. Strejcek Prague, Czech Republic	90,2% (41 patients)	Overview of a Pool of 41 Veins Treated in Routine Activity Over a 1-Month Period	AVF & UIP , San Antonio & Miami, 2023



A PRODUCT READY FOR SCALE-UP

Now a mature device: R&D as a market penetration driver





A PRODUCT READY FOR SCALE-UP

R&D as a market penetration driver: improving the product to enlarge addressable patients & centers



**Accelerate treatment
time**

From: 45 min to 1h

Down to: 30min



**Improve
ease of use**

From: a device for an ultrasound
trained medical doctor

Down to: an AI-guided, intuitive
device for a non-specialist



**Increase addressable
patient population**

From: mostly great saphenous* vein

Up to: more types of veins, larger, deeper



KEY ENABLERS:

AI – treatment assistance

ACOUSTICS – faster pulse

ROBOTICS – faster positioning


CLINICAL PRACTICE

Regular technical logs analysis identifies the most valuable improvement needs and drives R&D project priorities

SpeedPulse Clinical trial ongoing in Prague to test enhanced accelerated treatments acoustics



Why AI is the future of sonovein



Live imaging + robotics + AI engine => road to automated treatment

1 The SONOVEIN is permanently collecting US imaging and technical data

=> an integrated AI engine (GPU) could analyse and propose treatment action:

- Locate the vein / target
- Move to target
- Choose the adapted treatment parameters
- Deliver the therapy
- Move on to the next relevant location

AI algorithms are particularly efficient for these tasks

2 Leveraging its robotic and control features, the SONOVEIN could autonomously execute the proposed treatment action

AI enables simpler, more intuitive and significantly **faster** treatments, reducing the **learning curve** and providing new doctors with the **expertise** of an experienced KOL


sonovein[®]

Go-to-Market strategy



Go to market acceleration: Two business models

FAVORING RECURRING REVENUES



OUR CONSUMABLE

Single-use EPack™: ensures cooling and coupling

PAY-PER-USE

Paying per consumables,
all inclusive

w/ monthly min. quantity

Europe & USA

DIRECT SALES

Capital equipment
+
Consumables
+
Service

China, Middle East & R.o.W.

Diversified customer targets



Large centers:
hospitals, vein clinics



Small physician offices



Aesthetics and
cosmetics clinics



US market: a main Priority - FDA study follow-up completed



Source: AHA



1,000
Addressable sites



35%
Target market share



1,300
no. treatments per site
(yearly. avg)



450k+
Sonovein treatments

PIVOTAL STUDY

Main focus during the past two years
Top KOL onboarded

INITIAL COMMERCIAL TARGET

First 300 medical centers, revenue: \$100-200m/y



EU market: a commercial potential - and partnerships developments



1,500

Addressable sites



35%

Target market share



600

no. treatments per site
(yearly. avg)



315k+

Sonovein treatments

COMMERCIAL RAMP-UP

- Tier-1 sites at 100 or 150 treatments per year already
- Commercial relationships and existing recurring revenue
- Start of reimbursement in some countries (Spain, Italy)

PRODUCT REFINEMENT WITH KOL

- Fine-tuning product, protocols, and business offering
- Real-life field feedback and product needs collection
- Diversity of market practices addressed
- Data collection for next AI developments

INTERNATIONAL AWARENESS

- Sonovein's promotion by KOL in some of the largest European countries: Italy, France, Spain and the UK
- 50+ conferences by 15 KOL and 9 reference scientific papers
H1 2025: 13 presentations in 7 countries



Opportunities in China and Rest of the World

MARKET

- Largest potential varicose vein market in Asia
- Underserved market that could move directly to Sonovein's non-invasive solution to reach so far untreated patients

CHINESE MARKET PATH & PARTNERSHIP WITH FURUI

- Domestic product development and market access via Furui
- Global manufacturing
- JV's products sold only in China

NEXT MILESTONES

- Joint-Venture with Furui
- Prototyping
- Registration
- Clinical trial start (1-2 years)

MARKET

- Inbound demand from some countries, especially Middle East
- Business Model: Sonovein acquisition
- Large untapped market, not yet quantified

MARKET PATH

- Opportunistic sales of Sonovein
- Short term focus : Middle East
- Longer term focus: Latin America, Rest of Asia (India, etc)


ROW TARGETS

- ±100 Sonovein sold in 2030
- Consumables sales + Service attached to the machines





Growth roadmap and key milestones



sonovein[®]

A foundation for future perspectives



Sonovein success in Varicose Veins will open the way to other therapies

VARICOSE VEINS

Build platform

Succeed 1st commercial
breakthrough

THYROID NODULES

\$3.6B market
1,800,000 annual thyroid
nodules surgeries WW

Theraclion's
historical market

Latest Vein platform can
disrupt theThyroid market

BREAST CANCER

\$20B market, strong growth

Huge potential for HIFU
combined with traditionnal
therapies: immunology or
chemotherapy

Clinical studies ongoing at
University of Virginia with
Theraclion's device

MORE INDICATIONS

Hyperthermia - Possibility
to heat cancer tissue locally
prior to radiotherapy

Research programs ongoing

Other indications

sonovein®

Structured for Success




STRUCTURED FOR SUCCESS



A sharp and engaged management team

A dynamic leadership



Martin Deterre, PhD
CEO
15y. exp
Livanova, Pixium
M.I.T., Polytechnique
*Theraclion since Dec. 2020
as CTO
CEO since May 2023*

... Supported by a highly skilled and experienced team




Christophe Lamboeuf
Chief Financial Officer
30+y. exp, Mauna Kea,
Intrasense, Skytech, GE
THC since 2024



Marie Berne
Head of Marketing & Customer Relations
10y. exp, Dior, Figaret, EM Lyon,
THC since Oct. 2021



Michel Nuta, MD
Chief Medical Officer
30+y. exp, ex-VNUS
THC since Jan. 2013



Jérémie Anquez, PhD
Chief Scientific Officer
15+y. exp
Telecom ParisTech
THC since June 2010



Thibault Le Normand
Chief Business Officer
10y. exp
Sophysa
THC since May 2025



Gaylord Tallec, PhD
VP Operations
15y. exp
CEA, lifesearch
THC since Sept. 2016



Vivien Jourdainaud
VP QARA
10y. exp
Mauna Kea
THC since Oct. 2015



30 employees based in
Paris, France
**23 engineers, 6 PhD, 1
PharmD, 1 MD**



STRUCTURED FOR SUCCESS



An experienced and supportive board

An experienced chairman



Yann Duchesne
Chairman of the board

McKinsey 20y. Private
Equity 13y.
Theraclion since 2022

With highly qualified board members



Lijuan Deng
Board Member

17+y. in healthtech
Board of Echosens, Furui
THC since 2023



Mehdi El Glaoui, Pharm.D
Board Member

Ex-CEO Lab. Cassenne,
Wyeth, Marjorelle
THC since 2021



Claude Lenoir
Board Member

Former CEO of Echosens and
Air Liquide Medical Systems
THC since 2023



Cédric Bellanger
Board Member


CBML / Augusta
Real Estate & Capital Investment
fund manager
THC since 2022



THERACLION shareholding structure

SHAREHOLDERS

(as of December 31st, 2024)



FURUI (300049:CH): GENUINE STRATEGIC PARTNERSHIP

- **Theraclion's investor since 2016**
- **China JV created in 2017**
- **Replication of Echosens' Success:**
 - **Echosens (France):** +/-300 employees, global leader in non-invasive liver diagnostics.
 - **Furui lead development in China**, supports R&D in France and global commercial deployment.
 - Echosens China is a **key contributor to Echosens Global P&L**.



ALTHE



GLOSSARY

- **HIFU:** High Intensity Focused Ultrasound is a non-invasive therapeutic technique that uses non-ionizing ultrasonic waves to heat or ablate tissue.
- **Venous reflux or Chronic Venous Insufficiency (CVI):** occurs when veins no longer circulate blood properly. It often affects the leg veins, causing blood to pool and leading to swelling and discomfort.
- **Serious Adverse Events (SAE):** an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
- **CEAP classification:** the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification is an internationally accepted standard for describing patients with chronic venous disorders
- **FDA:** Food and Drug Administration



DISCLAIMER

This presentation does not constitute an offer to sell or a solicitation of a THERACLION share purchase offer.

Some information in this document may include projections and forecasts. THERACLION believes that these forward-looking statements are based on reasonable assumptions as at the date of this document, which are subject to numerous risks and uncertainties. As a result, the numbers and ratings provided may differ significantly from the projected figures. THERACLION neither undertakes nor has the obligation to update the forward-looking information contained in this presentation to reflect any unforeseen event or circumstance occurring after the date of this presentation.

The information contained in this document has been selected by the Group's General Management to present THERACLION and THERACLION's results. This document has not been independently verified. THERACLION makes no commitment as to the accuracy or completeness of this information. None of THERACLION's representatives can be held responsible for any loss resulting from the use of this presentation or its content.

Under no circumstances will THERACLION assume any responsibility for any investment or other decisions made on the basis of the information provided in this presentation. Readers are advised to review the company's financial information and the applicable AMF filings of the company before making any investment or other decision.



bit.ly/3KYQKJD

Thank you!

THERACLION

244 av. Pierre Brossolette

92240 Malakoff

T: +33 1 55 48 90 70

E: contact@theraclion.com

FOLLOW US ON **LINKEDIN** FOR UPDATES

APPENDIX



FY 2024 Financial Results





P&L : Net loss of 5,7 M€ in 2024

In K€	FY 2024	FY 2023	V%
Sales	830	1,822	(54%)
Other Income	1,332	2,095	
Total Operating Revenues	2,162	3,917	(45%)
Cost of Sales	1,428	330	333%
External operating expenses	3,222	2,602	24%
Comp & Ben.	3,357	3,154	6%
Other operating expenses	973	984	(1%)
Total operating expenses	8,981	7,070	27%
Operating profit	(6,819)	(3,152)	116%
Financial revenue/ (expense)	49	(1,955)	(102%)
non recurring profit / (loss)	30	384	(92%)
R&D tax credit	(984)	(1,049)	(6%)
Net Profit / (Loss)	(5,757)	(3,675)	(56.7%)



Balance sheet 2024 – Improved Working Capital


K€	FY 2024	FY 2023	Var.
Non-current assets	3,193	2,542	651
Including intangible assets	1,133	1,225	
Including tangible assets	858	106	
Of which non-current financial assets	1,202	1,211	
Current assets	8,273	16,122	(7,849)
Inventory	2,113	3,055	
Cash and cash equivalent	4,171	7,815	
Other assets	1,989	5,252	
Total Asset	11,466	18,664	(7,198)
Equity	-0.1	5,777	
Non current liabilities	6,290	6,290	
Including advances from BPI	6,290	6,290	
Current liabilities	5,176	6,597	(1,421)
Incl. Accruals for Risk & Curr. Exposure	119	215	
Incl. Loans (PGE)	1,292	1,947	
Total Liabilities	11,466	18,664	(7,198)



Cash flows 2024

Cash Flows details FY 2024

■ Increase ■ Decrease ■ Total



- Positive change in Working Capital drives global cash burn down to 3,6M€.
- Restated cash burn (Excl. Non recurring 2M€ of licensing fees paid in 2024) amounts to 5,6M€ => 0,45 K€ per month.

Libellé	FY 2024 12 months
Cash flow from operating activitie	
Profit / (Loss)	(5 757)
Elimination of amortization, dépréciation and provision	824
Revenue and expenses related to the discounting of repayable advances	
Others	
Change in WCR related to business activities	2 022
Net Cash from operating activities	(2 911)
Cash flow from investing activities	
Purchase of property, plant and equipment and intangible assets	(102)
Proceeds from sale of property, plant and equipment and intangible assets	(86)
Other cash flows from investing operations	
Cash flow from investing activities	(188)
Cash flow from financing activities	
Proceeds from issue of shares	110
Cash received from new loans issuance	
Reimbursement of debt	(655)
Other cash flows from financing operations	
Net cash flows from financing activities	(545)
Change in cash	(3 644)
Cash at the beginning of the period	7 815
Cash at the end of the period	4 171